2012 has been a very busy year for the MID-Frail partners and the study consortium has undergone some significant changes. CAIBER has left the consortium and the tasks for which they were responsible are in the process of being assumed by other partners (SERMAS, IDOP and, from January 2013, Niche Science & Technology Ltd). Everyone involved in MID-Frail owe a debt of gratitude to those at CAIBER, in particular María Sanchiz, for her invaluable contributions to the development of the project.
The changes to the consortium and associated new task distribution have been presented to the EU Commission as an amendment. It is hoped these will be accepted in the next 1–2 months and that the necessary budget transfers are granted speedily, to avoid any significant impact on the project. You can read more about developments in the latest newsletter [1].
The MID-Frail protocol has been finalised and the study registered on ClinicalTrials.gov. The entry details the various sub-studies involved in the project:
The project also include an randomized controlled ancillary study: SENSOLE for which the aim is to investigate the potential effects of vibrating insoles device on gait and posture.
Our vision is to advance the impact of ageing research in meeting current and emerging challenges. More information can be found at the MID‐Frail homepage [2].
References
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
